Soley Therapeutics Announces $200 Million Series C Financing to Propel Lead Oncology Programs into the Clinic and Scale Its Cell Stress Sensing Platform

Lead asset for acute myeloid leukemia (AML) on track for IND filing in 2026; second asset for solid tumor(s) entering IND-enabling studies Novel platform leverages proprietary cell stress sensing technology to discover first-in-class compounds Surveyor Capital (a Citadel Company) as primary investor with support from new and existing investors to advance Soley’s robust preclinical pipeline […]